Moderna Inc. [MRNA] is -46.53% lower this YTD. Is it still time to buy?


Moderna Inc. [NASDAQ: MRNA] gained 1.04% on the last trading session, reaching $135.80 price per share at the time. The company report on May 9, 2022 that Moderna to Host Annual Science and Technology Day on May 17, 2022.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that that it will host its in-person Science and Technology Day for analysts and investors at 9:00 a.m. ET on Tuesday, May 17 in Boston, MA.

Moderna’s Science and Technology Day will feature presentations from Stephen Hoge M.D., President, Melissa Moore Ph.D., Chief Scientific Officer, Scientific Affairs, and Moderna’s mRNA and technical development platform scientists with a focus on the Company’s newest advances from its commitment to basic and applied sciences.

Moderna Inc. represents 402.00 million in outstanding shares, while the company has a total market value of $57.08 billion with the latest information. MRNA stock price has been found in the range of $131.78 to $141.653.

If compared to the average trading volume of 7.25M shares, MRNA reached a trading volume of 9594201 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Moderna Inc. [MRNA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $227.62 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Redburn have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 01, 2022. The new note on the price target was released on January 26, 2022, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise from $135 to $180, while BofA Securities kept a Neutral rating on MRNA stock.

The Average True Range (ATR) for Moderna Inc. is set at 11.17, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 2.53. The Price to Book ratio for the last quarter was 3.20, with the Price to Cash per share for the same quarter was set at 24.07. Price to Free Cash Flow for MRNA in the course of the last twelve months was 4.38 with Quick ratio for the last quarter at 1.60.

Trading performance analysis for MRNA stock

Moderna Inc. [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.42. With this latest performance, MRNA shares dropped by -14.59% in over the last four-week period, additionally sinking by -42.70% over the last 6 months – not to mention a drop of -14.35% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 40.90, with the RSI for the last a single of trading hit 39.26, and the three-weeks RSI is set at 42.19 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 155.22, while it was recorded at 142.76 for the last single week of trading, and 262.18 for the last 200 days.

Moderna Inc. [MRNA]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of +71.89 and a Gross Margin at +84.53. Moderna Inc.’s Net Margin is presently recorded at +66.27.

Return on Equity for this stock inclined to 146.08, with Return on Assets sitting at 75.78.

Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.80.

Moderna Inc. [MRNA]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.

An analysis of insider ownership at Moderna Inc. [MRNA]

There are presently around $33,622 million, or 63.30% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 45,629,226, which is approximately -0.312% of the company’s market cap and around 5.20% of the total institutional ownership; BLACKROCK INC., holding 27,661,473 shares of the stock with an approximate value of $3.76 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $3.72 billion in MRNA stock with ownership of nearly 0.902% of the company’s market capitalization.

Positions in Moderna Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 594 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 19,557,550 shares. Additionally, 546 investors decreased positions by around 18,028,692 shares, while 122 investors held positions by with 210,000,023 shares. The mentioned changes placed institutional holdings at 247,586,265 shares, according to the latest SEC report filing. MRNA stock had 172 new institutional investments in for a total of 1,551,913 shares, while 215 institutional investors sold positions of 5,107,408 shares during the same period.